Wire · opportunities
FDA Grants Breakthrough Therapy Designation to Daretabart for Newly Diagnosed High ...
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
The US FDA has granted Breakthrough Therapy Designation to Daretabart for treating newly diagnosed high-risk neuroblastoma, aiming to accelerate development and review of this potentially impactful therapy.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You gain a shorter timeline to bring a new high-risk neuroblastoma treatment to market as FDA speeds development for breakthrough therapies like Daretabart. Accelerate your trial design and regulatory strategy to match this opportunity.
◆ Coverage
1 source · 18 Nov 2026
◆ Related on Wire
◆ Topics
Biotechfdabreakthrough-therapyneuroblastomaoncologydrug-development